Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.14 USD | +3.86% | -0.50% | -16.06% |
Financials (USD)
Sales 2024 * | 512M | Sales 2025 * | 617M | Capitalization | 3.21B |
---|---|---|---|---|---|
Net income 2024 * | -560M | Net income 2025 * | -484M | EV / Sales 2024 * | 5.74 x |
Net cash position 2024 * | 274M | Net cash position 2025 * | 405M | EV / Sales 2025 * | 4.55 x |
P/E ratio 2024 * |
-5.89
x | P/E ratio 2025 * |
-7.28
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.55% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | +3.86% | ||
1 week | +0.60% | ||
Current month | -5.64% | ||
1 month | -5.64% | ||
3 months | -25.24% | ||
6 months | +3.32% | ||
Current year | -16.06% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | -.--% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 40.14 | +3.86% | 1,518,406 |
24-05-30 | 38.65 | +1.34% | 666,156 |
24-05-29 | 38.14 | -3.05% | 532,826 |
24-05-28 | 39.34 | -2.48% | 818,934 |
24-05-24 | 40.34 | +1.10% | 407,482 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.06% | 3.21B | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- RARE Stock